Profil is the world's leading full service CRO for early phase clinical trials in diabetes, obesity, NAFLD/NASH and associated comorbidities. Due to this specialization, we can offer a unique combination of scientific excellence, reliable and fast patient recruitment and a vast portfolio of sophisticated methodologies to deliver a premium quality service tailored to your needs.

Our expertise enables us to be more than just a mere workbench. We design and carry out the best-in-class trials for our clients and deliver critical answers for further compound development.

Over the years, we have implemented numerous sophisticated methods for pharmacodynamic characterization of the effects of compounds and we have been involved in the development of all the currently available major anti-diabetic compounds.

One of our core technologies is the hyperinsulinemic euglycemic clamp, used to address action profiles of insulin and insulin analogues, beta cell function and insulin sensitivity.